Methods to Detect Amyloid Seeds Improve, Extend to Blood and Parkinson’s
Methods that trawl body fluids for amyloidogenic proteins are getting more sensitive and specific, and scientists are expanding the repertoire of oligomers they can detect.
ALL NEWS
6535 RESULTS
Sort By:
- Most Recent
- Most Commented
Tau2022 Global Conference (Virtual Meeting)
P-Tau217 Clock Predicts Alzheimer’s Progression Over 30 Years At Tau2022: Unknown Functions Emerge for Tau, LRRK2 Tau Triggers Neuroinflammation, But Mechanisms Vary by Disease Tau Haplotypes Hint at Transcriptional Changes, Ferroptosis Since Tau2020 was
AD/PD 2022: Advances in Science and Therapy (Hybrid Virtual and In-Person)
Gantenerumab Prevention Trial in Sporadic Alzheimer's Begins In First for the Field, α-Synuclein PET. Only for Multiple System Atrophy Using Lecanemab Trial Data to Determine Maintenance Dose Scientists Re-Analyze Aduhelm Data, Try to Parse Who Benef
Clinical Trials on Alzheimer's Disease (CTAD) 2021 (Hybrid In-Person/Virtual)
Aduhelm Lowers Tau; Registry to Track Real-World Performance Donanemab Phase 3 Puts Plasma p-Tau, Remote Assessments to the Test Plasma Aβ—First Sign of AD, But Tough to Measure Prospectively? More Tau Antibodies Bid Adieu; Semorinemab Keeps Foot in Door
DNA Nuclease Fans the Flames of Huntington’s Disease
Rare genetic variants that blunt FAN1 activity cause rapid expansion of CAG trinucleotide repeats in somatic cells.
Is This Mutation Pathogenic? Alzforum Updates System for Making This Call
Applied to more than 500 alleles in APP, PSEN1, and PSEN2, the new classification can help scientists gauge how pathogenic, or benign, a given variant might be
NIH Summit Wraps Up with Recommendations for Research
Outcomes emphasize big data, new technology, environmental and genetic risk in hopes of enabling precision medicine.
Non-Aβ, Non-Tau Drugs Tweak Markers, Cognition in Alzheimer’s, Huntington’s
Researchers at the online AAT-AD/PD meeting touted therapies that target neuroinflammation, synapses, epigenetic regulation, or the cortisol stress response.
The Rain in Spain: Move Over Higgins, AI Spots Speech Patterns
AI-powered apps catch changes in how a person speaks that may reveal cognitive decline in frontotemporal dementia and early Alzheimer’s. Can smartphones deliver biomarkers for trial enrollment and diagnosis?
Vienna: New Tack to See Amyloid Oligomers in Body Fluids
The ICAD featured that the interest in small Aβ aggregates has branched out far beyond the initial debates about whether they even exist and which forms are important...
Automated CSF Tests: Check. Blood Tests: In the Works
Clinical validation is showing automated Elecsys, Lumipulse assays to be reliable and predictive. The story on blood tests has turned from non-starter to intensely promising for broad-based screening.
Amyloid PET Aids Diagnosis. But Could CSF Do Just as Well?
Large IDEAS data set establishes that PET scans are valuable in clinical practice. Other studies suggest CSF biomarker ratios perform nearly as well.
AD GWAS in African Americans Confirms, Reshuffles AlzGene List
African Americans carrying a variant in a cholesterol-processing gene have double the risk for Alzheimer’s than non-carriers...
Geneticists Seek Out Rare Contributors to Alzheimer’s
New genes linked to early and late-onset AD offer up mechanistic insight, potential targets for treatment.
At AAN, Sights Set on Antisense Therapies for Diseases of the Brain
Antisense oligonucleotides are raising hopes for tackling a wide range of brain disorders—is the enthusiasm warranted?
Current Filters
No filters selected